A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
NOT ENROLLING
Trial ID:
NCT03170960 Protocol # :
17-492
Conditions
Urothelial Carcinoma
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Castration-resistant Prostate Cancer
Triple Negative Breast Cancer
Ovarian Cancer
Endometrial Cancer
Hepatocellular Carcinoma
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Colorectal Cancer
Head and Neck Cancer
Differentiated Thyroid Cancer
Lower Esophageal Cancer
Phase
I
Disease Sites
Other Male Genital
Urinary Bladder
Kidney
Other Urinary
Principal Investigator
McGregor, Bradley, A.
Site Investigator
Michaelson, M., Dror
Site Research Nurses
Aspinwall, Sheridan
Bowes, Brittany, N.
Bretta, Katherine, v.
Germon, Victoria
Graham, Christopher
Gurski, Carol
Healy, Erin, C.
Hindenach, Sarah
Hurley-Whalen, Christin
Katica, Dean
Lagerstedt, Elizabeth
Leisner, Claire
Markt, Denise, A.
Mingrino, Sage
Morrissey, Stephanie, C.
Pace, Amanda
Polinski, Karen
Porter, Kathryn
Prisby, Judith
Sawin, Mark
Theodore, Catherine
Walsh, Meghara
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #17-492
17-492